New Life Pharma LLC — FDA Warning Letter, 2026-04-14: CGMP/Adulterated and Unapproved New Drug/Misbranded
Letter issued · posted to fda.gov .
Subject as published: CGMP/Adulterated and Unapproved New Drug/Misbranded
TL;DR
FDA issued a Warning Letter to New Life Pharma LLC on 2026-04-14 citing: CGMP/Adulterated and Unapproved New Drug/Misbranded. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/new-life-pharma-llc-725661-04142026
Argus analysis
New Life Pharma LLC (MARCS-CMS 725661) received an FDA Warning Letter dated April 14, 2026 from the Center for Drug Evaluation and Research (CDER). The letter cites: CGMP/Adulterated and Unapproved New Drug/Misbranded. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on April 21, 2026.
CGMP citations typically reference 21 CFR Part 211 (finished pharmaceuticals) or Part 111 (dietary supplements), covering subjects such as identity testing of incoming components, validated cleaning procedures, batch-failure investigations, and stability program design. Repeat or systemic findings are what typically drive FDA toward import alert or consent decree escalation.
FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same CGMP (Current Good Manufacturing Practice) category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER New Life Pharma LLC MARCS-CMS 725661 — April 14, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA EMAIL WITH READ RECEIPT Reference #: 320-26-65 Product: Drugs Recipient: Recipient Name Mr. Arthur Leong Recipient Title Director, QA New Life Pharma LLC 265 Livingston Street Northvale , NJ 07647-1901 United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-65 April 14, 2026 Dear Mr. Leong: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, New Life Pharma LLC, 3012113519, at 265 Livingston Street, Northvale, from February 3 to February 13, 2026. Based on the inspection and a review of the evidence collected, we identified serious violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Your “Semaglutide Sterile Multi-Dose Vial” and “Tirzepatide Sterile Multi-Dose Vial” products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). These products are misbranded drugs under section 502(o) of the FD&C Act, 21 U.S.C. 352(o) because you did not properly register you firm or list your drugs with FDA. In addition, your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). Finally, during the inspection our FDA investigators documented that your firm delayed, denied, limited, and/or refused to permit an FDA inspection. Under section 501(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) 21 U.S.C. 351(j), your drugs are adulterated in that they have been manufactured, processed, packed, or held in an establishment where the owner or operator has delayed, denied, limited, and/or refused to permit inspection. Introducing or delivering these drugs for introduction into interstate commerce violates sections 301(a), 301(d), 301(p), and 505(a) of the FD&C Act, 21 U.S.C. 331(a), 331(d), 331(p), and 355(a). Unapproved New Drug Violations Your “Semaglutide Sterile Multi-Dose Vial” and “Tirzepatide Sterile Multi-Dose Vial” are “drugs” under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body. Multiple factors demonstrate that these products are intended for use as drugs. For example, your registration as a drug manufacturer and listing of a semaglutide injectable drug in FDA’s drug registration and listing system provides evidence of your intent for these products to be used as drugs. (see 21 CFR 207.77(c)). Additional evidence that your products are intended to be used as drugs (see 21 CFR 201.128) includes their composition, consisting o…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What FDA violations was New Life Pharma LLC cited for?
- The FDA Warning Letter to New Life Pharma LLC (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/Adulterated and Unapproved New Drug/Misbranded. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to New Life Pharma LLC?
- FDA issued the letter (MARCS-CMS 725661) on 2026-04-14 and posted it publicly on fda.gov on 2026-04-21.
- Is the FDA warning letter to New Life Pharma LLC publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/new-life-pharma-llc-725661-04142026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). New Life Pharma LLC — FDA Warning Letter, 2026-04-14: CGMP/Adulterated and Unapproved New Drug/Misbranded. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-new-life-pharma-llc-2026-04-14-cgmp
"New Life Pharma LLC — FDA Warning Letter, 2026-04-14: CGMP/Adulterated and Unapproved New Drug/Misbranded." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-new-life-pharma-llc-2026-04-14-cgmp.
Argus HQ Research. "New Life Pharma LLC — FDA Warning Letter, 2026-04-14: CGMP/Adulterated and Unapproved New Drug/Misbranded." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-new-life-pharma-llc-2026-04-14-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_new_life_pharma_llc_2026_04_14_cgmp_2026,
title = {New Life Pharma LLC — FDA Warning Letter, 2026-04-14: CGMP/Adulterated and Unapproved New Drug/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-new-life-pharma-llc-2026-04-14-cgmp},
note = {Accessed: July 13, 2026}
}